{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:04:16Z","timestamp":1785456256293,"version":"3.56.0"},"reference-count":30,"publisher":"Japan Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1507\/endocrj.ej22-0562","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T22:12:40Z","timestamp":1683756760000},"page":"777-786","source":"Crossref","is-referenced-by-count":3,"title":["Endocrinological evaluation of dawn phenomenon in patients with diabetes and comparison of insulin glargine U-100 biosimilar (Insulin Glargine BS Injection \u201cLilly\u201d) and glargine U-300 (Lantus XR): a randomized controlled study"],"prefix":"10.1507","volume":"70","author":[{"given":"Masanori","family":"Hasebe","sequence":"first","affiliation":[{"name":"Metabolism Internal Secretion Internal Medicine, Chigasaki Municipal Hospital, Kanagawa 253-0042, Japan"},{"name":"Endocrinology\/Diabetes and Metabolism, Yokohama City University Hospital, Kanagawa 236-0004, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Satoh","sequence":"additional","affiliation":[{"name":"Metabolism Internal Secretion Internal Medicine, Chigasaki Municipal Hospital, Kanagawa 253-0042, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Ito","sequence":"additional","affiliation":[{"name":"Metabolism Internal Secretion Internal Medicine, Chigasaki Municipal Hospital, Kanagawa 253-0042, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Tamura","sequence":"additional","affiliation":[{"name":"Metabolism Internal Secretion Internal Medicine, Chigasaki Municipal Hospital, Kanagawa 253-0042, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Terauchi","sequence":"additional","affiliation":[{"name":"Endocrinology\/Diabetes and Metabolism, Yokohama City University Hospital, Kanagawa 236-0004, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1 Watts LM, Manchem VP, Leedom TA, Rivard AL, Mckey RA (2005) Reduction of hepatic and adipose tissue glucocorticoid receptor expression with antisense oligonucleotides improves hyperglycemia and hyperlipidemia in diabetic rodents without causing systemic glucocorticoid antagonism. Diabetes 54: 1846\u20131853.","DOI":"10.2337\/diabetes.54.6.1846"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Chakravarty K, Cassuto H, Reshef L, Hanson RW (2005) Factors that control the tissue-specific transcription of the gene for phosphoenolpyruvate carboxykinase-C. Crit Rev Biochem Mol Biolt 40: 129\u2013154.","DOI":"10.1080\/10409230590935479"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Moller N, Jorgensen JO (2009) Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 30: 152\u2013177.","DOI":"10.1210\/er.2008-0027"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Cryer PE (2016) The physiology of glucose counterregulation. In: Hypoglycemia in diabetes: pathophysiology, prevalence and prevention (3rd). American Diabetes Association, Alexandria, USA: 29\u201362.","DOI":"10.2337\/9781580406499.02"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Cryer PE (2001) The prevention and correction of hypoglycemia. In: Jefferson LS, Cherrington AD (eds) Handbook of Physiology. Section 7, The Endocrine System. Volume II, The Endocrine Pancreas and Regulation of Metabolism. Oxford University Press, New York, USA: 1057\u20131092.","DOI":"10.1002\/cphy.cp070235"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Gerich JE (1988) Glucose counterregulation and its impact on diabetes mellitus. Diabetes 37: 1608\u20131617.","DOI":"10.2337\/diab.37.12.1608"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Campbell PJ, Bolli GB, Cryer PE, Gerich JE (1985) Sequence of events during development of the dawn phenomenon in insulin-dependent diabetes mellitus. Metabolism 34: 1100\u20131104.","DOI":"10.1016\/0026-0495(85)90153-2"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8 Schmidt MI, Hadji-Georgopoulos A, Rendell M, Margolis S, Kowarski A (1981) The dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation. Diabetes Care 4: 579\u2013585.","DOI":"10.2337\/diacare.4.6.579"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Campbell PJ, Bolli GB, Cryer PE, Gerich JE (1985) Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus: accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. N Engl J Med 312: 1473\u20131479.","DOI":"10.1056\/NEJM198506063122302"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10 Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, et al. (1990) Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 33: 52\u201359.","DOI":"10.1007\/BF00586461"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11 Monnier L, Collette C, Dejager S, Owens D (2013) Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care 36: 4057\u20134062.","DOI":"10.2337\/dc12-2127"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Monnier L, Colette C, Dejager S, Owens D (2015) The dawn phenomenon in type 2 diabetes: how to assess it in clinical practice? Diabetes Metab 2: 132\u2013137.","DOI":"10.1016\/j.diabet.2014.10.002"},{"key":"13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2337\/dc14-0006","volume":"38","author":"RH Becker","year":"2015","unstructured":"13 Becker RH, Dahmen R, Bergmann K, Lehmann A, Jax T, et al. (2015) New insulin glargine 300 units mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units mL-1. Diabetes Care 38: 637\u2013643.","journal-title":"Diabetes Care","ISSN":"https:\/\/id.crossref.org\/issn\/0149-5992","issn-type":"print"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Matsuhisa M, Koyama M, Cheng X, Takahashi Y, Riddle MC, et al. (2016) New insulin glargine 300 U\/mL <i>versus<\/i> glargine 100 U\/mL in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1). Dabetes Obes Metab 18: 375\u2013383.","DOI":"10.1111\/dom.12619"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Terauchi Y, Koyama M, Cheng X, Takahashi Y, Riddle MC, et al. (2016) New insulin glargine 300 U\/mL <i>versus<\/i> glargine 100 U\/mL in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2). Diabetes Obes Metab 18: 366\u2013374.","DOI":"10.1111\/dom.12618"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Schmidt MI, Lin QX, Gwynne JT, Jacobs S (1984) Fasting early morning rise in peripheral insulin: evidence of the dawn phenomenon in nondiabetes. Diabetes Care 7: 32\u201335.","DOI":"10.2337\/diacare.7.1.32"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17 Bolli GB, De Feo P, De Cosmo S, Perriello G, Ventura MM, et al. (1984) Demonstration of a dawn phenomenon in normal human volunteers. Diabetes 33: 1150\u20131153.","DOI":"10.2337\/diabetes.33.12.1150"},{"key":"18","unstructured":"18 Kruszynska YT, Home PD (1988) Night-time metabolic changes in normal subjects in the absence of the dawn phenomenon. Diabete Metab 14: 437\u2013442."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Porcellati F, Lucidi P, Bolli GB, Fanelli CG (2013) Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. Diabetes Care 36: 3860\u20133862.","DOI":"10.2337\/dc13-2088"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Yagasaki H, Kobayashi K, Saitou T, Nagamine K, Mitsui Y, et al. (2010) Nocturnal blood glucose and IGFBP-1 changes in type 1 diabetes: differences in the dawn phenomenon between insulin regimens. Exp Clin Endocrinol Diabetes 118: 195\u2013199.","DOI":"10.1055\/s-0029-1239518"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Radziuk J, Pye S (2006) Diurnal rhythm in endogenous glucose production is a major contributor to fasting hyperglycaemia in type 2 diabetes. Suprachiasmatic deficit or limit cycle behaviour? Diabetologia 49: 1619\u20131628.","DOI":"10.1007\/s00125-006-0273-9"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22 Monnier L, Collette C, Dunseath GJ, Owens DR (2007) The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 30: 263\u2013269.","DOI":"10.2337\/dc06-1612"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Boyle PJ, Avogaro A, Smith L, Shah SD, Cryer PE, et al. (1992) Absence of the dawn phenomenon and abnormal lipolysis in type 1 (insulin-dependent) diabetic patients with chronic growth hormone deficiency. Diabetologia 35: 372\u2013379.","DOI":"10.1007\/BF00401205"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24 Campbell PJ, Bolli GB, Gerich JE (1988) Prevention of the Dawn phenomenon (early morning hyperglycemia) in insulin-dependent diabetes mellitus by bedtime intranasal administration of a long-acting somatostatin analog. Metabolism 37: 34\u201337.","DOI":"10.1016\/0026-0495(88)90026-1"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Kovisto VA, Yki-Jarvinen H, Helve E, Karonen SL, Pelkonen R (1986) Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes 35: 78\u201382.","DOI":"10.2337\/diabetes.35.1.78"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Atiea JA, Luzio S, Owens DR (1992) The dawn phenomenon and diabetes control in treated NIDDM and IDDM patients. Diabetes Res Clin Pract 16: 183\u2013190.","DOI":"10.1016\/0168-8227(92)90115-8"},{"key":"27","unstructured":"27 Atiea JA, Aslan SM, Owens DR, Luzio S (1990) Early morning hyperglycaemia \u201cdawn phenomenon\u201d in non-insulin dependent diabetes mellitus (NIDDM): effects of cortisol suppression by metyrapone. Diabetes Res 14: 181\u2013185."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Kerner W, Navascues I, Torres AA, Pfeiffer EF (1984) Studies on the pathogenesis of the dawn phenomenon in insulin-dependent diabetic patients. Metabolism 33: 458\u2013464.","DOI":"10.1016\/0026-0495(84)90148-3"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Ostrovski I, Lovblom LE, Scarr D, Weisman A, Cardinez N, et al. (2020) Analysis of prevalence, magnitude and timing of the dawn phenomenon in adults and adolescents with type 1 diabetes: descriptive analysis of 2 insulin pump trials. Can J Diabetes 44: 229\u2013235.","DOI":"10.1016\/j.jcjd.2019.08.003"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Huang Y, Wang H, Li Y, Tao X, Sun J (2017) Poor sleep quality is associated with dawn phenomenon and impaired circadian clock gene expression in subjects with type 2 diabetes mellitus. Int J Endocrinol 2017: 4578973.","DOI":"10.1155\/2017\/4578973"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/70\/8\/70_EJ22-0562\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:48:30Z","timestamp":1715575710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/70\/8\/70_EJ22-0562\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej22-0562","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"EJ22-0562"}}